Every 424B that Terra Innovatum Global N.V. (NKLR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NKLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKLR filings page.
Terra Innovatum Global N.V. (NKLR) filed a prospectus supplement to its Form S-1 registering up to 5,475,593 Ordinary Shares issuable upon exercise of warrants, up to 94,804,436 Ordinary Shares, and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. On August 14, 2026, its Ordinary Shares closed at $6.09 on Nasdaq.
The attached current report describes the appointment of Katherine Williams as Chief Financial Officer of the U.S. subsidiary and as an executive director/CFO of Terra Innovatum Global N.V. Her package includes a base salary of $465,000, a one-time $40,000 sign-on bonus, and an annual performance-based MBO bonus opportunity between 50% and 250% of base salary, plus severance and change-in-control protections providing up to 18 months of salary, target bonus, 18 months of healthcare coverage, equity-vesting acceleration, and up to $30,000 of outplacement services in certain termination scenarios.
Terra Innovatum Global N.V. is updating a prior S-1 prospectus to cover up to 5,475,593 ordinary shares issuable upon exercise of warrants, 94,804,436 ordinary shares, and 40,200,000 ordinary shares issuable upon mandatory conversion of outstanding preferred shares. The company is pre-revenue, developing its 1 MWe SOLO micro‑modular nuclear reactor and targeting first deployment by 2028. For the quarter ended June 30 2026, it reported a net loss of $18,044 thousand and a six‑month net loss of $25,150 thousand, driven by higher general and administrative and development costs and large non‑cash fair value losses on share‑settled contingent liabilities and warrant liabilities. Cash and cash equivalents were $91,055 thousand against total liabilities of $214,015 thousand, resulting in a shareholders’ deficit of $(115,495) thousand. Management prepares the accounts on a going‑concern basis but discloses material weaknesses in internal control over financial reporting and continues to invest in regulatory engagement and engineering for the SOLO reactor.
Terra Innovatum Global N.V. filed a Prospectus Supplement No. 3 to register up to 94,804,436 Ordinary Shares, including up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. The supplement attaches a Form 8-K dated July 2, 2026 and updates the Prospectus dated December 15, 2025.
The company notes its Ordinary Shares trade on Nasdaq under the symbol NKLR; the closing price reported on Nasdaq on July 2, 2026 was $4.62. The supplement should be read with the Prospectus and prior amendments.
Terra Innovatum Global N.V. amends its S-1 prospectus to register up to 94,804,436 Ordinary Shares. The supplement specifically lists up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. The prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and notes the Company’s Nasdaq listing under the symbol NKLR; the closing price on July 2, 2026 was $4.62 per share. The Company reported cash and cash equivalents of $96,701 and total ordinary shares issued and outstanding of 110,500,908 as of June 29, 2026. This supplement updates the prospectus and must be read together with the Prospectus dated December 15, 2025.
Terra Innovatum Global N.V. registers up to 94,804,436 Ordinary Shares under a Prospectus Supplement No. 1 to its Registration Statement on Form S-1. The supplement also registers up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of preferred shares.
The Prospectus Supplement attaches the company’s Annual Report on Form 10-K filed on June 16, 2026 and updates the Prospectus dated December 15, 2025. The cover disclosure notes a Nasdaq closing price of $4.62 on July 2, 2026 and states there were 110,500,908 ordinary shares outstanding as of March 31, 2026.
Terra Innovatum Global N.V. is registering up to 140,480,029 Terra Shares for resale, plus up to 5,475,593 Ordinary Shares issuable upon exercise of outstanding warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of preferred shares. The resale shares include stock held by the SPAC sponsor, management, advisors, bridge loan lenders and PIPE investors following Terra’s business combination with GSR III Acquisition Corp.
The company will not receive proceeds from any shareholder resales, but could receive up to approximately $59.5 million if all warrants are exercised for cash, which it intends to use for general corporate and working capital purposes. Terra develops the SOLO micro modular nuclear reactor and has not yet generated revenue, reports operating losses and discloses substantial doubt about its ability to continue as a going concern, alongside significant regulatory, technological, market adoption and supply-chain risks. The filing warns that full resale of the registered shares could materially pressure the trading price of Terra’s stock.